title: Repopulation of ovarian cancer cells after chemotherapy.
abstract: The high mortality rate caused by ovarian cancer has not changed for the past thirty years. Although most patients diagnosed with this disease respond to cytoreductive surgery and platinum-based chemotherapy and undergo remission, foci of cells almost always escape therapy, manage to survive, and acquire the capacity to repopulate the tumor. Repopulation of ovarian cancer cells that escape front-line chemotherapy, however, is a poorly understood phenomenon. Here I analyze cancer-initiating cells, transitory senescence, reverse ploidy, and cellular dormancy as putative players in ovarian cancer cell repopulation. Under standard of care, ovarian cancer patients do not receive treatment between primary cytotoxic therapy and clinical relapse; understanding the mechanisms driving cellular escape from chemotherapy should lead to the development of low toxicity, chronic treatment approaches that can be initiated right after primary therapy to interrupt cell repopulation and disease relapse by keeping it dormant and, therefore, subclinical.
authors.forename: Carlos M
authors.initials: CM
authors.lastname: Telleria
references.citation: Anticancer Agents Med Chem. 2007 Jan;7(1):3-18
references.pmid: 17266502
references.citation: Front Biosci (Elite Ed). 2012 Jan 01;4:1528-41
references.pmid: 22201973
references.citation: Clin Cancer Res. 1995 Jun;1(6):599-606
references.pmid: 9816021
references.citation: Clin Cancer Res. 2003 Oct 1;9(12):4614-8
references.pmid: 14555537
references.citation: Semin Oncol. 2006 Apr;33(2 Suppl 6):S3-11
references.pmid: 16716797
references.citation: Cancer Treat Rev. 2007 Feb;33(1):9-23
references.pmid: 17084534
references.citation: Cancer Res. 2005 Apr 1;65(7):2795-803
references.pmid: 15805280
references.citation: Br J Cancer. 1994 Feb;69(2):299-306
references.pmid: 7905279
references.citation: Cancer Treat Res. 2002;112:1-26
references.pmid: 12481709
references.citation: Curr Med Chem. 2003 Feb;10(3):257-66
references.pmid: 12570712
references.citation: Int J Cancer. 2012 Jan 1;130(1):29-39
references.pmid: 21480217
references.citation: Cell Cycle. 2009 Oct 15;8(20):3274-84
references.pmid: 19770585
references.citation: Exp Cell Res. 2010 Aug 1;316(13):2099-112
references.pmid: 20457152
references.citation: Int J Oncol. 2009 Mar;34(3):743-55
references.pmid: 19212679
references.citation: Ann Oncol. 2011 Dec;22 Suppl 8:viii5-viii15
references.pmid: 22180401
references.citation: Cell. 2010 Apr 2;141(1):69-80
references.pmid: 20371346
references.citation: Cancer Res. 2009 Mar 15;69(6):2296-304
references.pmid: 19258501
references.citation: Methods Mol Med. 2004;88:267-73
references.pmid: 14634238
references.citation: Cell Biol Int. 2008 Sep;32(9):1031-43
references.pmid: 18550395
references.citation: Cancer Res. 2011 Jun 1;71(11):3991-4001
references.pmid: 21498635
references.citation: Nat Med. 2003 May;9(5):568-74
references.pmid: 12692539
references.citation: Curr Pharm Des. 2010;16(6):734-40
references.pmid: 20388083
references.citation: Cell Death Differ. 2011 Sep;18(9):1403-13
references.pmid: 21072053
references.citation: Stem Cells. 2009 Dec;27(12):2875-83
references.pmid: 19816957
references.citation: Gynecol Oncol. 2011 Jun 1;121(3):429-30
references.pmid: 21601106
references.citation: Stem Cells. 2012 Mar;30(3):415-24
references.pmid: 22267284
references.citation: Chem Rev. 2007 May;107(5):1387-407
references.pmid: 17455916
references.citation: Hum Pathol. 2011 Jul;42(7):918-31
references.pmid: 21683865
references.citation: Front Biosci (Elite Ed). 2012 Jan 01;4:2142-9
references.pmid: 22202026
references.citation: Cancer Lett. 2010 Aug 28;294(2):139-46
references.pmid: 20363069
references.citation: J Biol Chem. 2011 Oct 28;286(43):37813-29
references.pmid: 21878644
references.citation: Biochem Biophys Res Commun. 2007 Apr 20;355(4):855-9
references.pmid: 17307142
references.citation: Semin Oncol Nurs. 1993 Nov;9(4 Suppl 2):6-10
references.pmid: 7904378
references.citation: Stem Cells. 2012 Oct;30(10):2309-19
references.pmid: 22887854
references.citation: Bone Marrow Transplant. 1995 Jun;15(6):929-33
references.pmid: 7581093
references.citation: Nat Rev Cancer. 2009 Jun;9(6):415-28
references.pmid: 19461667
references.citation: Mol Cancer. 2012 Apr 26;11:26
references.pmid: 22537224
references.citation: Int J Gynecol Cancer. 2008 May-Jun;18(3):506-14
references.pmid: 17868344
references.citation: Lancet Oncol. 2000 Oct;1:86-93
references.pmid: 11905673
references.citation: J Biomol Screen. 2010 Aug;15(7):820-9
references.pmid: 20639504
references.citation: Nat Rev Cancer. 2011 Sep 23;11(10):719-25
references.pmid: 21941283
references.citation: Front Biosci (Landmark Ed). 2011 Jan 01;16:368-92
references.pmid: 21196176
references.citation: Biochim Biophys Acta. 2007 Jan;1775(1):5-20
references.pmid: 17027159
references.citation: Trends Cell Biol. 2012 Apr;22(4):211-9
references.pmid: 22245068
references.citation: J Clin Invest. 2008 Dec;118(12):3837-40
references.pmid: 19033653
references.citation: Cancer Discov. 2012 Jan;2(1):16-8
references.pmid: 22585163
references.citation: Nat Rev Cancer. 2007 Aug;7(8):573-84
references.pmid: 17625587
references.citation: Cell Biol Int. 2011 Jul;35(7):687-95
references.pmid: 21250945
references.citation: Lancet. 2010 Oct 2;376(9747):1155-63
references.pmid: 20888993
references.citation: J Clin Invest. 2008 Dec;118(12):3917-29
references.pmid: 19033662
references.citation: Mech Ageing Dev. 2009 Jan-Feb;130(1-2):24-32
references.pmid: 18538372
references.citation: EMBO J. 2003 Aug 15;22(16):4212-22
references.pmid: 12912919
references.citation: Cell Cycle. 2006 Aug;5(16):1756-9
references.pmid: 16880738
references.citation: Cancer Res. 2005 Apr 1;65(7):2825-31
references.pmid: 15805283
references.citation: Drug Discov Today. 2012 Mar;17(5-6):269-76
references.pmid: 22314100
references.citation: Cell Death Differ. 2008 Jul;15(7):1153-62
references.pmid: 18404154
references.citation: Cytometry A. 2003 Jan;51(1):1-6
references.pmid: 12500299
references.citation: Endocrinology. 2012 Apr;153(4):1593-602
references.pmid: 22416079
references.citation: Cancer Biol Ther. 2004 Feb;3(2):207-18
references.pmid: 14726689
references.citation: Oncogene. 2009 Jan 15;28(2):209-18
references.pmid: 18836486
references.citation: Lancet Oncol. 2007 Sep;8(9):813-21
references.pmid: 17765190
references.citation: Clin Cancer Res. 1999 Apr;5(4):767-74
references.pmid: 10213211
references.citation: Nat Rev Cancer. 2012 Jun 14;12(7):487-93
references.pmid: 22695393
references.citation: Trends Pharmacol Sci. 1992 Apr;13(4):134-6
references.pmid: 1350385
references.citation: BMC Cancer. 2012 Jun 22;12:200
references.pmid: 22642877
references.citation: Am J Pathol. 2010 Sep;177(3):1053-64
references.pmid: 20651229
references.citation: Cell Biol Int. 2005 Dec;29(12):1012-8
references.pmid: 16310380
references.citation: Nat Rev Cancer. 2005 Jul;5(7):516-25
references.pmid: 15965493
references.citation: Cell Biol Int. 2005 Dec;29(12):1084-97
references.pmid: 16316756
references.citation: Br J Clin Pharmacol. 2004 Jun;57(6):756-63
references.pmid: 15151521
references.citation: Jpn J Clin Oncol. 2001 Mar;31(3):93-9
references.pmid: 11336328
references.citation: PLoS Comput Biol. 2012 Jan;8(1):e1002316
references.pmid: 22275856
references.citation: Cell Death Differ. 2008 Mar;15(3):555-66
references.pmid: 18064041